Anixa Biosciences Secures USAN Approval for CAR-T Therapy Name, Clearing Path for Global Commercialization
Event summary
- Anixa Biosciences received USAN approval for 'liraltagene autoleucel' as the non-proprietary name for its FSHR-targeted CAR-T therapy for recurrent ovarian cancer on February 2, 2026.
- The approval follows prior international naming approval by the WHO's INN Expert Committee.
- Liraltagene autoleucel is currently in a Phase 1 trial (NCT05316129) for recurrent ovarian cancer, conducted in partnership with Moffitt Cancer Center.
- The therapy uses a novel CER-T technology licensed from The Wistar Institute.
The big picture
The USAN approval is a key step in Anixa's strategy to bring its novel CAR-T therapy to market, aligning with broader industry trends toward targeted immunotherapies for recurrent cancers. The therapy's unique CER-T technology differentiates it from traditional CAR-T approaches, potentially offering a new treatment option for ovarian cancer patients. The company's partnerships with leading cancer research institutions underscore its focus on leveraging external expertise to advance its pipeline.
What we're watching
- Trial Execution
- The pace at which the Phase 1 trial of liraltagene autoleucel progresses will determine the next regulatory milestones and potential path to market.
- Commercialization Strategy
- How Anixa leverages the universal non-proprietary name to position the therapy for global commercialization will be critical for its market entry strategy.
- Partnership Dynamics
- The effectiveness of Anixa's collaborations with Moffitt Cancer Center and other research institutions will influence the therapy's development and approval timeline.
Related topics